By Michele Maatouk
Date: Friday 09 Aug 2024
LONDON (ShareCast) - (Sharecast News) - Merck said on Friday that it has agreed to buy biotech firm Curon's CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, for up to $1.3bn.
Under the terms of the deal, Merck will buy full global rights to CN201 for an upfront cash payment of $700m. Curon is also eligible to receive up to $600m in milestone payments associated with the development and regulatory approval of CN201.
Dr. Dean Y. Li, president of Merck Research Laboratories, said: "We continue to identify opportunities to expand and diversify our pipeline.
"Early clinical data have provided robust evidence for the potential of CN201 to target and deplete circulating and tissue B cells with the potential to treat a range of malignant and autoimmune diseases."
CN201 is currently being evaluated in Phase 1 and Phase 1b/2 clinical trials for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and relapsed or refractory B-cell acute lymphocytic leukemia (ALL), respectively.
Merck said preliminary data suggest CN201 has activity in patients with relapsed or refractory B-cell hematologic malignancies and is well tolerated, with the potential to induce significant and sustained reductions in B-cell populations.
Merck plans to evaluate CN201 as a treatment for B-cell malignancies as well as investigate its potential to provide a novel, scalable option for the treatment of autoimmune diseases.
Email this article to a friend
or share it with one of these popular networks:
Currency | US Dollars |
Share Price | $ 99.86 |
Change Today | $ 2.42 |
% Change | 2.48 % |
52 Week High | $132.96 |
52 Week Low | $96.31 |
Volume | 15,665,040 |
Shares Issued | 2,531.63m |
Market Cap | $252,809m |
Beta | 0.19 |
RiskGrade | 92 |
Strong Buy | 10 |
Buy | 11 |
Neutral | 4 |
Sell | 0 |
Strong Sell | 0 |
Total | 25 |
Time | Volume / Share Price |
15:59 | 100 @ $99.89 |
15:59 | 100 @ $99.88 |
15:59 | 184 @ $99.98 |
15:59 | 100 @ $99.98 |
15:59 | 184 @ $99.98 |
You are here: research